Bristol-Myers Squibb

Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
Multiple Myeloma
Flag link:
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Motley Fool
NASH
liver disease
Viking Therapeutics
Madrigal Pharmaceuticals
Pfizer
Bristol-Myers Squibb
Gilead Sciences
Flag link:
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Endpoints
Bristol-Myers Squibb
Opdivo
China
Flag link:
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
Flag link:
ASCO18: 3 unanswered questions from oncology's largest conference
ASCO18: 3 unanswered questions from oncology's largest conference
Biopharma Dive
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
immunotherapy combinations
non-small cell lung cancer
Flag link:
ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
Fierce Pharma
Bristol-Myers Squibb
biomarkers
ASCO 2018
Opdivo
Flag link:
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
Flag link:
Ahead of ASCO, BMS' Opdivo leads Merck's Keytruda in U.S. sales—but not for long, analyst predicts
Ahead of ASCO, BMS' Opdivo leads Merck's Keytruda in U.S. sales—but not for long, analyst predicts
Fierce Pharma
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Flag link:
5 Best-Selling Orphan Drugs in the U.S.
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
Flag link:
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Endpoints
Roche
Tecentriq
anti-PD-L1
non-squamous non-small cell lung cancer
Merck
Bristol-Myers Squibb
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
BMY Is Rapidly Advancing Its First-Line NSCLC Research Program
BMY Is Rapidly Advancing Its First-Line NSCLC Research Program
Market Realist
Bristol-Myers Squibb
Opdivo
non-small cell lung cancer
Yervoy
Flag link:
Cancer drug spending climbs, with top winners earning lion's share
Cancer drug spending climbs, with top winners earning lion's share
Biopharma Dive
drug spending
oncology
Merck
Bristol-Myers Squibb
Flag link:
5 takeaways from the first look at cancer's biggest conference
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
Flag link:
Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen
Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen
Fierce Pharma
physicians
digital marketing
Bristol-Myers Squibb
Biogen
Celgene
Flag link:
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
CP Wire
Bristol-Myers Squibb
Opdivo
Yervoy
metastatic non-small cell lung cancer
EMA
Europe
Flag link:
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
Bristol-Myers Squibb
non-small cell lung cancer
Opdivo
Yervoy
Flag link:
A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins
A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins
Medical Marketing and Media
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Flag link:
Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers
Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers
Forbes
Flatiron Health
M&A
Roche
Bristol-Myers Squibb
real-world evidence
Flag link:
Bristol-Myers profit tops Street view, raises 2018 forecast
Bristol-Myers profit tops Street view, raises 2018 forecast
Reuters
Bristol-Myers Squibb
earnings
Flag link:

Pages